Findings seen in patients with posterior circulation stroke and with no planned thrombectomy who received alteplase 4.5 to 24 hours after stroke onset.

Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research suggests.

No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge. (HealthDay News) — For patients with ischemic stroke, tenecteplase ...

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes.

MONDAY, March 24, 2025 (HealthDay News) -- For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes ...

And now, research shows that tenecteplase works just as well as the standard clot-busting drug alteplase used to treat strokes, according to findings published recently in JAMA Network Open.

A major shift in stroke care is underway as tenecteplase outperforms alteplase. This new treatment could redefine recovery outcomes worldwide.

TUESDAY, Feb. 18, 2025 (HealthDay News) -- For patients with acute ischemic stroke (AIS) whose symptoms began 4.5 to 24 hours earlier, alteplase is associated with a higher percentage of patients ...

Alteplase Also Shows Its Mettle for Late Strokes in HOPE Trial — Positive data for patients considered non-candidates for endovascular therapy ...

Alteplase improves stroke recovery by over 50% when given up to 24 hours after symptom onset, offering hope for patients with delayed access to treatment.

The clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke, according to preliminary late ...

In a randomized clinical trial, giving the clot-busting medication alteplase up to 24 hours after stroke symptoms first appeared increased the odds of better recovery by 50% compared to those who ...